Amevive Wisdom Acquired From Real-Time Evidence (A.W.A.R.E™) Program
1 other identifier
observational
426
1 country
30
Brief Summary
Purpose: To develop a real time national clinical database to support and share best practices,
- 1.To generate hypotheses for future clinical research
- 2.To understand how AMEVIVE is used in routine clinical practice/real world setting.
- 3.AMEVIVE dosing
- 4.Number of courses
- 5.Concomitant treatment
- 6.Response to treatment (patient and physician global assessments)
- 7.Status of other psoriasis-related medical conditions
- 8.Time to re-treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2005
Typical duration for all trials
30 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2005
CompletedFirst Submitted
Initial submission to the registry
August 31, 2006
CompletedFirst Posted
Study publicly available on registry
September 4, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2008
CompletedNovember 17, 2011
November 1, 2011
2.9 years
August 31, 2006
November 15, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Understand how AMEVIVE is used in routine clinical practice/real world setting
End of study
Study Arms (1)
1
Dermatologic patients in Canada for which Amevive is clinically indicated
Eligibility Criteria
Dermatologic patients in Canada
You may qualify if:
- Amevive is clinically indicated for the patient
You may not qualify if:
- Amevive is contraindicated for the patient
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (30)
Unknown Facility
Calgary, Alberta, T2S 3B3, Canada
Unknown Facility
Calgary, Alberta, T3A 2N1, Canada
Unknown Facility
Edmonton, Alberta, T5J 3S9, Canada
Unknown Facility
Edmonton, Alberta, T5K 1X3, Canada
Unknown Facility
Surrey, British Columbia, V3R6A7, Canada
Unknown Facility
Vancouver, British Columbia, V5Z 3Y1, Canada
Unknown Facility
Vancouver, British Columbia, V5Z 4E8, Canada
Unknown Facility
Victoria, British Columbia, V8V 3P9, Canada
Unknown Facility
Victoria, British Columbia, V8V 4X3, Canada
Unknown Facility
Winnipeg, Manitoba, R3C 1R4, Canada
Unknown Facility
Moncton, New Brunswick, E1C 8X3, Canada
Unknown Facility
Saint John, New Brunswick, E2M 3W5, Canada
Unknown Facility
St. John's, Newfoundland and Labrador, A1B 3A1, Canada
Unknown Facility
St. John's, Newfoundland and Labrador, A1B 3E1, Canada
Unknown Facility
St. John's, Newfoundland and Labrador, A1B 4S8, Canada
Unknown Facility
Halifax, Nova Scotia, B3H 124, Canada
Unknown Facility
Barrie, Ontario, L7M 6L7, Canada
Unknown Facility
Concord, Ontario, L4K 5V2, Canada
Unknown Facility
Hamilton, Ontario, L8N 3H7, Canada
Unknown Facility
London, Ontario, N6A 3H7, Canada
Unknown Facility
London, Ontario, N6H 1S9, Canada
Unknown Facility
Markham, Ontario, L3P 1A8, Canada
Unknown Facility
Oakville, Ontario, L6K 1E1, Canada
Unknown Facility
Toronto, Ontario, M5S 1B6, Canada
Unknown Facility
Waterloo, Ontario, N2J 1C4, Canada
Unknown Facility
Windsor, Ontario, N8W 5L7, Canada
Unknown Facility
Montreal, Quebec, H2K 4L5, Canada
Unknown Facility
Montreal, Quebec, H3G 1A1, Canada
Unknown Facility
Québec, Quebec, G1J 1X7, Canada
Unknown Facility
Sainte-Foy, Quebec, G1V 4X7, Canada
Related Publications (5)
Searles G, Bissonnette R, Landells I, Shear NH. Preface: real-world clinical experience with alefacept-the Amevive Wisdom Acquired from Real-World Evidence (AWARE) study. J Cutan Med Surg. 2009 Dec;13 Suppl 3:S107-12. doi: 10.2310/7750.2009.00028. No abstract available.
PMID: 20053322BACKGROUNDBissonnette R, Searles G, Landells I, Shear NH, Papp K, Lui H, Gulliver WP, Lynde C. The AWARE study: methodology and baseline characteristics. J Cutan Med Surg. 2009 Dec;13 Suppl 3:S113-21. doi: 10.2310/7750.2009.00029.
PMID: 20053323BACKGROUNDLandells I, Searles G, Bissonnette R, Shear NH, Vender R, Lui H. Efficacy outcomes in patients using alefacept in the AWARE study. J Cutan Med Surg. 2009 Dec;13 Suppl 3:S122-30. doi: 10.2310/7750.2009.00030.
PMID: 20053324BACKGROUNDSearles G, Bissonnette R, Landells I, Shear NH, Papp K, Lui H. Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE study. J Cutan Med Surg. 2009 Dec;13 Suppl 3:S131-8. doi: 10.2310/7750.2009.00031.
PMID: 20053325BACKGROUNDWexler D, Searles G, Landells I, Shear NH, Bissonnette R, Papp K, Poulin Y, Langley R, Gulliver WP. Update on alefacept safety. J Cutan Med Surg. 2009 Dec;13 Suppl 3:S139-47. doi: 10.2310/7750.2009.00032.
PMID: 20053326BACKGROUND
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Use Central Contact
Astellas Pharma Canada, Inc.
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 31, 2006
First Posted
September 4, 2006
Study Start
June 1, 2005
Primary Completion
May 1, 2008
Study Completion
May 1, 2008
Last Updated
November 17, 2011
Record last verified: 2011-11